Negative Immune Checkpoint Protein, VISTA, Regulates the CD4+ T(reg) Population During Sepsis Progression to Promote Acute Sepsis Recovery and Survival

Chyna C. Gray1,2, Bethany Biron-Girard2, Michelle E. Wakeley2, Chun-Shiang Chung2, Yaping Chen2, Yael Quiles-Ramirez2, Jessica D. Tolbert2 and Alfred Ayala1,2*

1 Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, United States, 2 Division of Surgical Research, Department of Surgery, Brown University, Providence, RI, United States

Sepsis is a systemic immune response to infection that is responsible for ~35% of in-hospital deaths and over 24 billion dollars in annual treatment costs. Strategic targeting of non-redundant negative immune checkpoint protein pathways can cater therapeutics to the individual septic patient and improve prognosis. B7-CD28 superfamily member V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an ideal candidate for strategic targeting in sepsis. We hypothesized that immune checkpoint regulator, VISTA, controls T-regulatory cells (T(reg)), in response to septic challenge, thus playing a protective role/reducing septic morbidity/mortality. Further, we investigated if changes in morbidity/mortality are due to a T(reg)-mediated effect during the acute response to septic challenge. To test this, we used the cecal ligation and puncture model as a proxy for polymicrobial sepsis and assessed the phenotype of CD4+ Tregs in VISTA-gene deficient (VISTA−/−) and wild-type mice. We also measured changes in survival, soluble indicators of tissue injury, and circulating cytokines in the VISTA−/− and wild-type mice. We found that in wild-type mice, CD4+ Tregs exhibit a significant upregulation of VISTA which correlates with higher Treg abundance in the spleen and small intestine following septic insult. However, VISTA−/− mice have reduced Treg abundance in these compartments met with a higher expression of Foxp3, CTLA4, and CD25 compared to wild-type mice. VISTA−/− mice also have a significant survival deficit, higher levels of soluble indicators of liver injury (i.e., ALT, AST, bilirubin), and increased circulating proinflammatory cytokines (i.e., IL-6, IL-10, TNFα, IL-17F, IL-23, and MCP-1) following septic challenge. To elucidate the role of Tregs in VISTA−/− sepsis mortality, we adoptively transferred VISTA-expressing Tregs into VISTA−/− mice. This adoptive transfer rescued VISTA−/− survival to wild-type levels. Taken together, we propose a protective Treg-mediated role for VISTA by which inflammation-induced tissue injury is suppressed and improves survival in early-stage murine sepsis. Thus, enhancing VISTA expression or adoptively transferring VISTA+ Tregs in early-stage sepsis may provide a novel therapeutic approach to ameliorate inflammation-induced death.

Keywords: Vista, sepsis, regulatory T cells, cytokines, liver injury, Foxp3, CTLA4, CD25
1 INTRODUCTION

Despite exhaustive research on sepsis over the last 50 years (1) there remains no effective patho-physiological treatment options nor molecular methods of diagnosis. The incidence of sepsis has not improved, with sepsis accounting for ~35% of non-cardiac deaths during intensive care unit hospitalization, accounting for ~1 in 5 deaths worldwide (2), and it was the consensus cause of death assigned to those dying from COVID-19 infection (3). At >24 billion dollars in annual treatment costs, sepsis presents an economic as well as a healthcare burden (4). Historically, sepsis clinical trials have targeted the initial pro-inflammatory response by inhibiting cytokines in septic patients (5, 6). Efficacy was not universal, and treatment predisposed patients to fatal secondary infections (7).

Immune checkpoint blockade (ICB) has been used to ameliorate disease pathology with greater precision and success than many immune-directed therapies (8). Our laboratory, among others, has demonstrated that negative checkpoint regulator (NCR) targeting improves survival in preclinical sepsis models, but success has been limited in clinical trials (9–15). Strategic targeting of non-redundant NCR pathways has the potential to cater therapeutics to the individual septic patient and improve prognosis (16–18).

B7-CD28 superfamily member V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an ideal candidate for such potential strategic targeting in sepsis (18, 19). VISTA is a 55–65-kDa type 1 transmembrane protein and has unique biology that set it apart from all other NCRs (20, 21).

VISTA can act as a receptor or a ligand binding in VISTA : VISTA interactions, with VSIG-3, or with PSGL-1 depending on the cell it is expressed on (22, 23). VISTA regulation is also temporally distinct, acting as the earliest NCR of peripheral tolerance. Under steady-state conditions, VISTA promotes quiescence of naïve CD4+ T cells to prevent self-reactivity (24). Under inflammatory conditions, VISTA suppresses effector CD4+ T cell function (17, 20), maintains the T regulatory cell (Treg) pool size, and promotes induced Treg (iTreg) generation (25). This CD4+ T cell-specific modularity makes VISTA a specific and non-redundant regulator of the acute T cell response (24–27).

Septic patients experience a reduced number/frequency of splenic and thymic T cells, decreased cytokine production, and increased expression of exhaustion markers (28, 29). In murine sepsis models, there is a significant loss of CD4+ T cell frequency which impacts survival (30). Our laboratory, among others, has demonstrated that Treg play an indispensable role in the acute septic response, resolving inflammatory tissue damage and improving survival (31–34).

Based on the findings from our laboratory and others, we set out to determine if the immune checkpoint regulator VISTA controls T-regulatory cells (Treg), in response to septic challenge, thus playing a protective role and reducing septic morbidity/mortality. Further, we investigated if changes in morbidity/mortality were due to a Treg-mediated effect during the acute response to a septic challenge.

2 MATERIAL AND METHODS

2.1 Mice

Male C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Animals obtained from our outside vendor were acclimated no less than 7 days, and often longer [maximum ~5 weeks], prior to utilizing these animals in the studies described here. During this period, they were housed in the Rhode Island Hospital (RIH) rodent facility (12-h: 12-h light/dark cycle, 23°C–25°C, 30%–70% humidity) where they received standard care and diet (standard rodent chow)/water ad libitum. All protocols were carried out in the morning (8–11 a.m.) and were performed in accordance with the National Institutes of Health guidelines and as approved by the Animal Use Committee of Rhode Island Hospital (AWC# 5064-18 & 5054-21). VISTA−/− mice were produced at the Brown University Transgenic Facility using CRISPR/Cas9 technology. Guide RNA sequences for the 5’ deletion site: 395_Vsir_ex2upsgRNA1: CTTAGTAAACAGCCACCAT 396_Vsir_ex2upsgRNA2: GCTTAGTAAACAGCCACCA 398_Vsir_ex7sgRNA1: ATGTGCACATTGATCTATG GC (18-mer) 399_Vsir_ex7sgRNA2: GTGCCTAAAAGACTGTCCA

The initial genotyping strategy and PCR results for G1 and F0 generations are described in Supplemental Figure 1. A routine genotyping of VISTA−/− mice was performed on tail biopsy samples collected after weaning. Tail samples were processed for PCR and treated with custom 25-nmol DNA oligos from Integrated DNA Technologies (Coralville, IA, USA). Following PCR amplification, samples were run on an SDS-Page gel and imaged for gene deletion analysis and validation. Male mice with appropriate base-pair deletion were used for downstream studies. All mice were housed, bred, and maintained at the Rhode Island Hospital Central Research Facilities.

2.2 Patients

Septic/critically ill patients who were admitted to trauma and surgical intensive care units, between July of 2018 and February of 2020, were enrolled in this study per institutional review board approval at Rhode Island Hospital (IRB study # 413013). Inclusion criteria for the study were trauma or sepsis-related critical illness requiring ICU admission. Patients were excluded from the study if they were pregnant or had previous lymphoma or leukemia diagnosis. Patient demographics from the day of blood draw were used to calculate the Acute Physiology of Chronic Health Evaluation II (APACHE II) score (Table 1). Healthy volunteers (age- and sex-matched) were enrolled in this study to serve as the control group.

2.3 CLP Model

Cecal ligation and puncture (CLP) as described previously (35–37) was performed on wild-type C57BL/6 and VISTA−/− male mice aged 8–10 weeks. Following midline laparotomy, the cecum was ligated ~1 cm above the cecal tip and punctured twice with a 22-G needle. Cecal contents were extruded into the
intraperitoneal cavity. The abdomen was closed using a sterile PDO suture. Mice were treated with lidocaine on the muscle layer and a subcutaneous injection of 1 ml Lactated Ringer’s solution. The choice of male animals was made to maximize our ability to initially see an experimental difference septic response based on previous reports that male mice did poorer in response to these experimental stressors of septic (CLP) challenge than pro-estrus stratified female mice (38, 39). Mice were euthanized 24 h post procedure (based on the experiment as described in Figure 1), and tissues were harvested for downstream studies.

2.4 Flow Cytometry

2.4.1 Mouse Cell Phenotyping

The spleen, thymus, and intestine were harvested from mice 24 h following sham or CLP procedure. The spleen and thymus tissues were homogenized using frosted slides, and red blood cells were lysed using a Na⁺Cl⁻ gradient. Small intestinal tissue was processed using the Lamina Propria Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany: cat# 130-097-410) according to the manufacturer protocol. The total cell number from each sample was assessed using Trypan blue stain and

| TABLE 1 | Patient demographics. |
|----------|------------------------|
|          | Healthy Controls       | Patients        | p-value |
| Number   | 8                      | 8               | –       |
| Age      | 48.5 +/- 17.2          | 58.8 +/- 16.6   | 0.25    |
| Male gender | 5 (62.5%)             | 6 (75%)        | 0.62    |
| WBC      | –                      | 10.8 +/- 5.0 x 10⁶/ml | –       |
| APACHE II score | –                   | 19.9 +/- 5.2    | –       |
| Mortality | –                      | 2 (25%)        | –       |
| Active infection | –                   | 7 (87.5%)      | –       |

![FIGURE 1](image-url) | Experimental timeline for study. (A) WT and VISTA<sup>+</sup> mice underwent sham or CLP procedure, and tissues/blood were harvested for downstream analysis via flow cytometry or spectrophotometry. (B) WT and VISTA<sup>+</sup> mice underwent a CLP procedure, and survival was tallied for 14 days. Surviving mice were euthanized on the 15th day. (C) WT mice were injected with Jurkat T<sub>reg</sub>, and tissues were harvested 2 days postinjection for downstream analysis and validation of adoptive transfer via flow cytometry. (D) VISTA<sup>+</sup> mice were injected with Jurkat T<sub>reg</sub> then underwent CLP 2 days postinjection, and survival was tallied for 14 days. Surviving mice were euthanized on the 15th day.
hemicyctometer counting at ×10 magnification. Samples were diluted to 10^6 cells/ml in FACS buffer (2 mM EDTA, 0.5% BSA, PBS), Fc blocked, and stained with the following monoclonal anti-mouse antibodies: CD4-BV421 (BioLegend, San Diego, CA, USA, Cat# 100438, RRID: AB_11203718), CD8a-BV510 (BioLegend Cat# 100752, RRID: AB_2563057), CD69-FITC (Miltenyi Biotec Cat# 130-103-950, RRID: AB_2659081), PD-1H/VISTA-PE (BioLegend Cat# 143708, RRID: AB_11150599), CD25-PE/Cyanine7 (BioLegend Cat# 101916, RRID: AB_2616762), and CD125/CTLA-4-PerCP/Cyanine5.5 (BioLegend Cat# 106316, RRID: AB_2564474). Following initial staining, cells were fixed using 4% paraformaldehyde and permeabilized using the True Nuclear Transcription Buffer Set (BioLegend: cat# 424401) according to the manufacturer’s protocol. Permeabilized cells were stained with anti-mouse FOXP3-Alexa Fluor 647 (BioLegend: cat# 126408). To compensate for spectral overlap, UltraComp eBeads Plus Compensation Beads (Thermo Fisher Scientific, Waltham, MA, USA: cat# 01-3333-41) were used according to the manufacturer’s protocol. Fluorescence minus one (FMO) controls were used to determine positive expression gates during analysis using FlowJo software.

### 2.4.2 Human Cell Phenotyping

Whole blood was drawn from patients and healthy controls, collected in heparin-treated tubes, treated with Ficoll Histopaque-1077, and centrifuged to isolate leukocytes. The leukocyte layer was isolated, washed with PBS, and centrifuged. Cells were counted using a hemicyctometer and Trypan blue then diluted to 10^6 cells/ml in FACS buffer (2 mM EDTA, 0.5% BSA, PBS). Cells were Fc blocked and stained with the following monoclonal anti-human antibodies: CD3-VioBlue (Miltenyi Biotec: Cat# 130-113-133, RRID: AB_2725961) and VISTA-APC (Thermo Fisher Scientific: Cat# 17-1088-42, RRID: AB_2744704). Fluorescence minus one (FMO) control was used to determine positive expression gates during analysis using FlowJo software.

### 2.4.3 Adoptive Transfer Validation

For adoptive transfer, the pMSCV-mouse Foxp3-EF1α-GFP-T2A-puro stable Jurkat cell line (System Biosciences, Palo Alto, CA, USA: cat# TCI110C1), referred to as Jurkat Tregs, was harvested from culture, pelleted via centrifugation, and resuspended in HBSS (Thermo Fisher: cat# 24020117) at 2 × 10^6 cells/400 μl. 400 μl of Jurkat Treg suspension or HBSS vehicle control was loaded into a syringe and administered to mouse via intraperitoneal injection. Spleen, thymus, and small intestine samples were harvested 48 h post adoptive transfer and processed as described in the previous section. Cells were stained with CD4-BV421 (BioLegend: Cat# 100438, RRID: AB_11203718) and VISTA/PD-1H-APC (BioLegend: Cat# 143709, RRID: AB_11219607). A FMO control was used to determine VISTA-positive expression gates during analysis using FlowJo software.

### 2.5 Colorimetric Assays for Morbidity Study

To assess indices of tissue injury, blood was collected from mice 24 h following sham or CLP procedure via cardiac puncture using a heparin-coated syringe. Blood sample was centrifuged at 10,000 rpm, and supernatant (plasma) was collected and stored at -80°C. For tissue injury assays, plasma was analyzed using the following kits according to the manufacturer’s protocol: Urea Nitrogen (BUN) Colorimetric Detection Kit (Invitrogen, Carlsbad, CA, USA, cat# E1ABUN), Creatine Kinase Activity Assay Kit (Sigma-Aldrich, St. Louis, MO, USA: cat# MAK116), Alkaline Aminotransferase (ALT) Activity Assay Kit (Sigma-Aldrich: cat# MAK052), Aspartate Aminotransferase (AST) Activity Assay Kit (Sigma-Aldrich: cat# MAK055), Amylase Assay Kit (Colorimetric) (Abcam, Cambridge, MA, USA: cat# ab102523), and Bilirubin Assay Kit (Direct Colorimetric) (Abcam: cat# ab235627).

### 2.6 Multiplex Cytokine Analysis

Plasma samples were collected and stored as described in the previous section. To assess the cytokine concentration in plasma samples, the following multiplex kits were used according to the manufacturer’s instruction: LEGENDplex Mouse Inflammation Panel (13-plex) with a V-bottom plate (BioLegend, cat# 740446) and LEGENDplex MU Th Cytokine Panel (12-plex) with VbP VO3 (BioLegend, cat# 741044). Multiplex experiments were carried out using MACSQuant Analyzer 10 (Miltenyi Biotec). Data were analyzed using the LEGENDplex software suite (BioLegend).

### 2.7 In Vitro Viability Assay

Jurkat T_{regS} were cultured in RPMI complete medium with 13F3 (Bio X Cell, Lebanon, NH, USA, Cat# BE0310, RRID: AB_2736990) or Ig control (Bio X Cell Cat# BE0091, RRID: AB_1107773) for 30 min at 37°C, 5% CO2 then stained with alamarBlue (Bio-Rad, Hercules, CA, USA: product code BUF012A) according to the manufacturer’s protocol. Sample absorbance was measured every 24 h for 7 days using the Bio-Rad spectrophotometer. Viability was calculated according to the manufacturer’s protocol.

### 2.8 In Vitro Cytokine Analysis

Jurkat T_{regS} were cultured in RPMI complete medium with 13F3 (Bio X Cell Cat# BE0310, RRID: AB_2736990) or Ig control (Bio X Cell Cat# BE0091, RRID: AB_1107773) overnight at 37°C, 5% CO2. Treated cells were then stimulated with 5 µl of plasma from CLP mouse for 2 h prior to harvest from culture. Cells were centrifuged, and supernatant was collected for multiplex analysis using LEGENDplex MU Th Cytokine Panel (12-plex) with VbP VO3 (BioLegend: cat# 741044). Multiplex experiments were carried out using MACSQuant Analyzer 10 (Miltenyi Biotec). Data were analyzed using the LEGENDplex software suite (BioLegend).

### 2.9 Statistical Analysis

Statistical significance between two groups was determined using either a two-tailed Student’s unpaired t test for parametric data or the Mann–Whitney U test for the non-parametric test. Statistical significance between multiple groups was determined using either an ordinary one-way ANOVA for parametric data or the Kruskal–Wallis test for non-parametric data. Alpha was set
to 0.05 as the cutoff for statistical significance using Prism 9.3.0 (GraphPad Software) statistical software.

3 RESULTS

3.1 VISTA Expression Inversely Correlates With T-Cell Population Abundance in Septic Mice and Critically Ill Patients

Several research groups have shown that during acute sepsis progression there is a significant loss in T cell abundance in the spleen and thymus in both the murine CLP model (29, 40–42) and septic patients (43–46). In this study, we found that C57BL/6 wild-type (WT) mice exhibited a higher VISTA expression on CD4+ T cells (Figure 2A) and reduced CD4+ T cell population abundance (Figure 2B) in the spleen following septic challenge.

We enrolled a total of 8 critically ill patients from the trauma and surgical ICUs at a single level-1 trauma center. There was no significant difference between patients and healthy controls regarding gender or age. 87.5% of patients had an active ongoing source of infection at the time of draw, 62.5% required mechanical ventilation, and 37.5% were actively on vasopressor at the time of draw. 25% required dialysis due to critical illness. The average APACHE II score for the population was 19.9 (Table 1).

Sources of infection included necrotizing soft tissue infections of the lower extremities, intra-abdominal abscesses after perforated hollow viscus injuries, and bacteremia. 75% of enrolled patients met systemic inflammatory response syndrome (SIRS) criteria, 63% met sepsis criteria, and 38% met septic shock criteria (47).

We found that critically ill patients experience a higher VISTA expression on circulating CD3+ T cells (Figure 2C) despite reduced CD3+ T cell population abundance (Figure 2D) in circulation. These results suggest that the relationship between VISTA expression and T-cell abundance observed in our murine model of sepsis appear to have a potential correlate in the critically ill septic patient. To further explore the role of VISTA in the sepsis-induced T-cell response and better understand its potential contribution to septic morbidity, we created a global VISTA gene-deficient (VISTA-/-) mouse strain using CRISPR/Cas9 technology that could be examined to address this question (Figures 2E, F).

Le Tulzo et al. found that T cells become polarized into functionally distinct helper T-cell subsets in sepsis (44), and it is well documented that the regulatory T-cell (T_{reg}) subset increases during the acute septic response (46, 48, 49). In light of this, we chose to initially determine how VISTA impacted sepsis-induced T_{reg} polarization by comparing the CD4+Foxp3+ T_{reg} populations in WT as opposed to VISTA-/- mice via flow cytometry (Supplementary Figure 2).
3.2 CD4+ Treg Abundance Increases Following Septic Challenge, But the CD4+ Treg Population Is Significantly Smaller in Peripheral T-Cell Compartments of VISTA-/- Mice Compared to WT Mice

We found that in the WT spleen, there is a significant increase in total proportion of CD4+ Tregs and VISTA+CD4+ Tregs following CLP (Figures 3A–C). VISTA-/- mice exhibit decreased abundance of total CD4+ Tregs in the spleen (Figures 3B, C). In the thymus, we observe no change in VISTA expression on the Treg populations between sham and CLP WT mice (Supplementary Figures 3A, D); however, VISTA-/- mice have higher total abundance of CD4+ Tregs and CD4+CD8+ Tregs compared to WT mice (Supplementary Figures 3B, E). In the intraepithelial compartment of the small intestine, the frequency of VISTA+CD4+ Tregs increases significantly following CLP (Figure 4A) and VISTA-/- mice have less CD4+ Tregs under steady-state (sham) and inflammatory (CLP) conditions compared to WT mice (Figures 4B, C). We did not observe any trends in the lamina propria compartment of the small intestine (Supplementary Figure 4).

3.3 CD4+ Tregs Demonstrate Compensatory Upregulation of Several Checkpoint Proteins and Suppressive Factors in VISTA-/- Mice

The loss in CD4+ Tregs in VISTA-/- mice lead us to ask if the cell-surface expression signature, as it related to suppressive function of these cells, was altered by CLP. In the spleen, Foxp3, CTLA4, and CD25, but not CD69, are significantly upregulated on CD4+ Tregs in VISTA-/- mice compared to WT mice under steady-state and inflammatory conditions (Figures 5A–D). In the thymus (Figures 6A–G), CD25 is significantly upregulated on CD4+ Tregs in VISTA-/- mice compared to WT mice under steady state and inflammatory conditions (Figure 6C). CD4+ Tregs upregulate CD69 following CLP in WT and VISTA-/- mice (Figure 6D). We also found that Foxp3, CTLA4, and CD25 are significantly upregulated on CD4+CD8+ Tregs in WT mice compared to VISTA-/- mice under steady-state and inflammatory conditions (Figures 6E–G). In the lamina propria compartment, we observe a significant upregulation of CTLA4 on CD4+ Tregs in VISTA-/- mice (Supplementary Figure 5B). However, this trend is not observed in the small intestinal intraepithelial compartment (Supplementary Figure 6).

3.4 VISTA-/- Mice Have Higher Th17-Related Cytokine Production Compared to WT Mice Following Septic Challenge

To expand from the Treg phenotyping described above, we sought to measure the abundance of several cytokines in circulation implicated in the helper T cell response (Figures 7A–J). We found that VISTA-/- mice have significantly higher circulating IL-17F and IL-23 compared to WT mice post CLP (Figures 7G, I).

3.5 Compensatory Upregulation of Foxp3, CTLA4, and CD25 on Peripheral Treg Populations Correlates With Decreased Survival in VISTA-/- Mice

Based on the apparent compensatory upregulation of suppressive Treg mediators, we decided to compare the mortality and morbidity of VISTA-/- as opposed to WT mice when subjected to CLP.
to CLP (Figures 8A–J). We found that VISTA−/− mice had significantly decreased survival, which coincided with increased blood bilirubin, ALT, and AST 24 h following CLP (Figures 8A, D–G). VISTA−/− mice also present a more proinflammatory systemic cytokine profile (Figures 9A–J). These mice exhibit higher circulating IL-6, IL-10, TNF-α, and MCP-1 compared to WT mice post CLP (Figures 9C, D, G, I).

3.6 Adoptive Transfer of VISTA-Expressing Tregs to VISTA−/− Mice Rescues Survival to WT Levels Following CLP

To establish the contribution of VISTA+ Tregs to survival in murine sepsis, we chose to adoptively transfer pMSCV-mouse Foxp3-EF1α-GFP-T2A-puro stable Jurkat cells, hereby referred to as Jurkat Tregs, into VISTA−/− mice prior to CLP. 48 h post adoptive transfer, Jurkat Tregs accumulate in the spleen, thymus, and small intestine (Supplementary Figures 7A–D) and express high levels of VISTA (Supplementary Figures 7E–H). Based on these results, we performed the adoptive transfer 48 h before CLP and then subsequently assessed overall survival. We found that, following Jurkat Treg adoptive transfer, VISTA−/− mice had comparable survival to WT mice post CLP (Figure 10A).

4 DISCUSSION

Since its initial discovery, VISTA has been implicated in diverse immune-related pathologies driven by both innate and adaptive cells (20–27, 50–54). In a preliminary study, we found that septic mice and critically ill patients exhibit a higher proportion of VISTA+ T cells as compared to healthy controls. Based on these results, we set out to determine the impact of VISTA expression on regulatory T cells (Tregs) in murine sepsis. The CD4+ Treg plays a vital role in peripheral tolerance, regulation of effector cells, and prevention of bystander tissue damage under inflammatory and steady-state conditions as reviewed by Corthay (55). In sepsis, peripheral Tregs increase significantly in vivo studies. Jurkat Tregs were pretreated with a commercially available VISTA-neutralizing antibody, 13F3, or antibody control then stained with alamarBlue. alamarBlue is a redox indicator used to measure metabolic activity as a readout for viability. The concentration of alamarBlue was assessed via a spectrophotometer every 24 h for 7 days. We found that there was a significant reduction in viability following treatment and this reduction was maintained for 7 days without additional 13F3 treatment (Figure 10B). Upon in vitro acute stimulation of Jurkat Tregs with plasma from septic mice, these cells produce several helper T cell-related cytokines (Figures 10C–I) but failed to produce IFN-γ, IL-4, or IL-17A (Supplementary Figure 8). Interestingly, 13F3-treated Jurkat Tregs produce lower levels of IL-9, IL-10, and IL-17F following acute stimulation (Figures 10E, F, H).
and correlate with patient outcomes and lymphoproliferative pathology as reviewed by Jiang et al. (56, 57).

4.1 The Treg Population Is Composed of Several Subpopulations That Arise From Diverse Stimuli and Developmental Programs

The Treg classification as a distinct T cell lineage has been a point of contention due to the inherent plasticity of Tregs and the lack of a definitive "Treg" marker as effector T cells can transiently express Treg markers upon activation. Forkhead/winged-helix transcription factor box P3 (Foxp3) is arguably the most reliable Treg marker in mice and was used to delineate effector T cells and Tregs in this study (55, 58, 59). CD4+Foxp3+ T cells are potent suppressors of effector CD4+ T cells, CD8+ T cells, natural killer (NK) cells, dendritic cells (DCs), and B cells under inflammatory conditions (55).

4.2 VISTA Plays a Role in T-Cell Polarizing Cytokine Production and CD4+ Treg Abundance in Sepsis

In this study, we found that VISTA expression and total CD4+ Treg abundance increase significantly during the acute septic response. Further, this increase in peripheral Treg abundance is dependent on VISTA expression. We also found that VISTA expression plays a role in orchestrating the cytokine response to septic challenge. Cytokines provide contextual immunologic cues that shape cell lineage determination and plasticity. Higher levels of IL-17F, IL-6, and IL-23 promote CD4+ T cell polarization toward a Th17 phenotype, and higher concentrations of these cytokines may explain the reduced Treg abundance observed in VISTA−/− mice (60, 61). Previous studies found that VISTA regulated the Treg-Th17 polarization axis in mice (25), further supporting our results in the context of sepsis.
4.3 VISTA-/- Mice Experience Compensatory Upregulation of Several Endogenous Mediators of \( T_{\text{reg}} \) Suppression Such as CTLA4, Foxp3, and CD25 Under Steady-State Conditions

Interestingly, CTLA4 expression regulates the turnover and maintenance of \( T_{\text{reg}} \)s at steady state while Foxp3 regulates \( T_{\text{reg}} \) function and lineage commitment (62–64). A steady-state \( T_{\text{reg}} \) pool is requisite for preventing autoimmune lymphoproliferative pathology (65). Several groups have shown that VISTA-/- mice do not exhibit overt autoimmune pathologies under tolerogenic conditions (26, 53, 66). Therefore, we posit that the higher baseline expression of CTLA4, Foxp3, and CD25 in VISTA-deficient CD4+ \( T_{\text{reg}} \)s represents an inherent compensatory mechanism to sustain peripheral tolerance under tolerogenic conditions.

4.4 In the Acute Immune Response to Infection, as Observed With Our Murine Model of Sepsis, Compensatory Upregulation of CTLA4, Foxp3, and CD25 by CD4+ \( T_{\text{reg}} \)s Is Insufficient

An explanation may lie in the efficacy of CTLA4, Foxp3, and/or CD25-mediated suppression in our model. CD4+ \( T_{\text{reg}} \)s utilize diverse contact-dependent and independent mechanisms to exert immune suppression (35–37, 67, 68). For example, CTLA4-expressing \( T_{\text{reg}} \)s bind to B7-1/2 on antigen-presenting DCs, promoting trans-endocytosis of B7-1/2 and preventing DC-mediated activation of effector T cells. CD25 scavenges IL-2 from the environment, reduces IL-2 activation of effector T cells via competitive inhibition, and regulates the function of mature DCs (69).

Another mechanism by which \( T_{\text{reg}} \)s exert immune suppression is by directly polarizing the monocyte lineage commitment from M1 to M2 macrophages (69, 70). M1 macrophages produce proinflammatory cytokines and exacerbate inflammation-derived tissue injury in sepsis (71). Two potent M1 cytokines, IL-6 and MCP-1, are highly upregulated in VISTA-/- mice following septic challenge. M1-mediated pathology is particularly profound in the liver during infection (72), which may explain the increased acute liver injury observed in septic VISTA-/- mice.

4.5 Higher M1-Associated Cytokines and Apparent Liver Injury in VISTA-/- Mice Represents a Possible Lapse in the Suppressive Capacity of VISTA-/- \( T_{\text{reg}} \)s Despite Compensatory Upregulation of CTLA4, Foxp3, and CD25

To determine if VISTA-/- \( T_{\text{reg}} \)s contribute to the survival deficit observed in VISTA-/- mice, we adoptively transferred VISTA-
overexpressing Jurkat Tregs into VISTA-/- mice prior to septic challenge. We found that addition of Jurkat Tregs into VISTA-/- mice rescues survival to wild-type levels. Upon VISTA blockade in vitro, the Jurkat Tregs exhibited reduced proliferative capacity and production of IL-9 and IL-10. Treg-derived IL-9 plays a significant role in recruiting other suppressive immune cells, such as mast cells, to suppress bystander tissue damage as observed in a murine nephrotoxic serum nephritis model (73). Treg-derived IL-10 is required to regulate effector T cells during acute inflammation (74, 75).

A recent study was published demonstrating a survival benefit upon VISTA antibody blockade prior to CLP (76). Importantly, in the Tao et al. study they utilized WT mice. However, it has also been shown that VISTA-gene-deficient mice have a predisposition to proinflammatory immune activation in several disease contexts (17, 20, 26, 66). Based on prior studies and our results, we believe that the VISTA-gene-deficient mice develop a predisposition to proinflammatory tissue injury that is exacerbated by CLP, thus resulting in a survival deficit. Consequently, acute VISTA blockade with an exogenous antibody in a developmentally normal WT mouse, as used in the Tao et al. study, might yield different results than observed in VISTA-/- mice in our study.

In conclusion, we found that WT mice have increased VISTA+CD4+ Tregs and increased total CD4+ Tregs in the spleen and small intestine post CLP. This increase in total CD4+ Treg abundance is lost in VISTA-/- mice; however, VISTA-/- CD4+ Tregs have a higher expression of Foxp3,
**FIGURE 8** | VISTA−/− mice have significantly worse survival and morbidities following septic challenge. (A) 14-day survival following CLP [WT: n = 28, VISTA−/−: n = 26]. (B) Creatine kinase activity [WT-sham: n = 9, WT-CLP: n = 9, VISTA−/−sham: n = 10, VISTA−/−-CLP: n = 10]. (C) Blood urea nitrogen [WT-sham: n = 4, WT-CLP: n = 9, VISTA−/−sham: n = 6, VISTA−/−-CLP: n = 9]. (D) α-Amylase activity [WT-sham: n = 9, WT-CLP: n = 6, VISTA−/−sham: n = 5, VISTA−/−-CLP: n = 6]. (E) Direct bilirubin concentration [WT-sham: n = 5, WT-CLP: n = 5, VISTA−/−sham: n = 3, VISTA−/−-CLP: n = 4]. (F) Alanine aminotransferase activity [WT-sham: n = 4, WT-CLP: n = 8, VISTA−/−sham: n = 4, VISTA−/−-CLP: n = 8]. (G) Aspartate aminotransferase activity [WT-sham: n = 4, WT-CLP: n = 8, VISTA−/−sham: n = 4, VISTA−/−-CLP: n = 8] from plasma samples of wild-type and VISTA−/− mice. (B–G) Summary graphs show mean ± SEM; significance *p < 0.05; **p < 0.01.

**FIGURE 9** | VISTA−/− mice have significantly higher levels of several proinflammatory cytokines following septic challenge. (A–J) Plasma cytokine concentration of wild-type and VISTA−/− mice. Summary graphs show mean ± SEM [WT-sham: n = 10, WT-CLP: n = 10, VISTA−/−sham: n = 10, VISTA−/−-CLP: n = 10]; significance *p = 0.05; *p < 0.05; **p < 0.01; ***p < 0.001.
CTLA4, and CD25 relative to WT mice. VISTA-/- mice also have an altered cytokine profile including higher IL-6, IL-10, TNF-a, IL-17F, IL-23, and MCP-1 relative to WT mice. VISTA-/- mice have higher indices of acute liver injury (i.e., bilirubin, ALT, and AST) and reduced survival post CLP compared to WT mice. Interestingly, we were able to rescue VISTA-/- survival to WT levels by adoptively transferring VISTA-expressing Jurkat Tregs into VISTA-/- mice prior to CLP. In addition, treating Jurkat Tregs with a VISTA-neutralizing antibody in vitro reduces viability and cytokine production. We can conclude from these experiments that VISTA expression plays a pivotal role in promoting acute CD4+ Treg survival/stability and regulating the cytokine milieu in acute sepsis to confer a survival benefit.

### 4.6 Future Considerations

This study has raised questions as to the mechanism by which VISTA promotes Treg survival. Interestingly, Foxp3 and VISTA are both under the transcriptional regulation of p53 and HIF-1α. In fact, p53-Foxp3 and HIF1α-Foxp3 induction are indispensable for protective Treg suppression under inflammatory conditions (24, 77–79). The tentative relationship between VISTA and Foxp3 expression provide an additional line of query regarding Treg plasticity. Another area for further investigation concerns the effector immune cells that are non-redundantly regulated by VISTA+ Tregs. Based on results from this study, VISTA may act as a non-redundant marker for the Treg subset responsible for regulating M1/M2 polarization and limiting acute liver injury in sepsis. More work must be done to fully elucidate these mechanisms; however, we think this study contributes a novel perspective on checkpoint regulator, VISTA, in the acute sepsis response.

### DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by institutional review board approval at Rhode Island Hospital (IRB study # 413013). The patients/participants provided their written informed consent to participate in this study. All protocols were performed in accordance with the National Institutes of Health guidelines and as approved by the Animal Use Committee of Rhode Island Hospital (AWC# 5064-18 and 5054-21).

AUTHOR CONTRIBUTIONS

CG provided substantial contribution to the conception of this project, experiment design, data acquisition, and data analysis. CG also wrote the initial draft of the manuscript and participated in the revision steps of the manuscript. BB-G provided initial contribution to the conception of this project. MW enrolled patients and healthy controls, collected samples, and acquired human data. C-SC aided in small intestine sample isolation for flow cytometry studies. YC performed the initial survival study of VISTA−/− and WT mice and performed routine genotyping and husbandry of VISTA−/− mice. YQ-R performed initial ELISAs that supported multiplex experiments and results. JT generated preliminary data that contributed to the initial conception of this project. AA provided guidance throughout the conception and execution of this project. All authors reviewed this manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the National Institutes of Health (R35 GM118097 [provided for costs of supplies/animals/reagents, and portions of salary for AA, CG], R25 GM083270 [provided for a portion salary for CG], T32 GM065085 [provided fellowship support for MW], T32 HL134625 [provided fellowship support for BB-G], T35 HL67704 [provided fellowship support for YQ-R, JD]).

ACKNOWLEDGMENTS

The VISTA−/− mouse model was created at the Brown University Mouse Transgenic and Gene Targeting Facility that is supported by a grant from the National Institute of General Medical Sciences (P30 GM103410) from the National Institutes of Health.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.861670/full?supplementary-material

REFERENCES

1. Kadri SS, Rhee C, Strich JR, Morales MK, Hohmann S, Menchaca J, et al. Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data. Chest (2017) 151(2):278–85. doi: 10.1016/j.chest.2016.07.010
2. Rudd KE, Johnson SC, Aages KM, Shackelford KA, Tsoi D, Kievan DR, et al. Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet (2020) 395 (10219):200–11. doi: 10.1016/S0140-6736(19)32989-7
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet (2020) 395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3
4. Rhee C, Dantas R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA (2017) 318(13):1241–9. doi: 10.1001/jama.2017.13383
5. Hotchkiss RS, Monneret G, Heffernan DS, Chung CS, Lomas-Neira J, et al. Mechanisms of Indirect Acute Lung Injury: A Novel Role for the Coinhibitory Receptor, Programmed Death-1. Ann Surg (2012) 255(1):158–64. doi: 10.1097/SLA.0b013e31823433ca
6. Huang X, Chen Y, Chung CS, Yuan Z, Monaghan SF, Wang F, et al. Identification of B7-H1 as a Novel Mediator of the Innate Immune/Proinflammatory Response as Well as A Possible Myeloid Cell Prognostic Biomarker in Sepsis. J Immunol (2014) 194(2):1091–9. doi: 10.4049/jimmunol.1302252
7. Wakeley ME, Shubin NJ, Monaghan SF, Gray CC, Ayala A, Heffernan DS. Herpes Virus Entry Mediator (HVM): A Novel Potential Mediator of Trauma-Induced Immunosuppression. J Surg Res (2020) 245:610–8. doi: 10.1016/j.jss.2019.07.009
8. Xu S, Yang Q, Bai J, Tao T, Tang L, Chen Y, et al. Blockade of Endothelial, But Not Epithelial, Cell Expression of PD-L1 Following Severe Shock Attenuates the Development of Indirect Acute Lung Injury in Mice. Am J Physiol Lung Cell Mol Physiol (2020) 318(4):L801–12. doi: 10.1152/ajlun.00108.2019
9. Hutchins NA, Wang F, Wang Y, Chung CS, Ayala A. Kupffer Cells Potentiate Liver Sinusoidal Endothelial Cell Injury in Sepsis by Ligating Programmed Cell Death Ligand-1. J Leukoc Biol (2013) 94(5):963–70. doi: 10.1189/jlb.0413051
10. Wu Y, Chung CS, Chen Y, Monaghan SF, Patel S, Huang X, et al. A Novel Role for Programmed Cell Death Receptor Ligand-1 (PD-L1) in Sepsis-Induced Intestinal Dysfunction. Mol Med (2017) 22:830–40. doi: 10.2119/molmed.2016.00150
11. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in Sepsis: A Novel Understanding of the Disorder and a New Therapeutic Approach. Lancet Infect Dis (2013) 13(3):260–8. doi: 10.1016/S1473-3099(13)70001-X
17. Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye J, et al. Coinhibitory Receptor PD-1H Preferentially Suppresses CD4+ T-Cell-Mediated Immunity. J Clin Invest (2014) 124(5):1966–75. doi: 10.1172/JCI74589
18. Deng J, Le Mercier I, Kuta A, Noelle RJ. A New VISTA on Combination Therapy for Negative Checkpoint Regulator Blockade. J Immunother Cancer (2016) 4:86. doi: 10.1186/s40428-016-0190-5
19. Kondo Y, Ohno T, Nishii H, Harada K, Yagita H, Azuma M. Differential Contribution of Three Immune Checkpoint (VISTA, CTLA-4, PD-1) Pathways to Antitumor Responses Against Squamous Cell Carcinoma. Oral Oncol (2016) 57:54–60. doi: 10.1016/j.oraloncology.2016.04.005
20. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-Induced Human Lymphocyte Apoptosis and Cytokine Production in Sepsis. J Leukoc Biol (2015) 97(3):326–32. doi: 10.1128/JLB.4MA1213-647RR
21. Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. VISTA Is an Acidic pH-Selective Ligand for PSGL-1. Nature (2019) 574(7779):565–70. doi: 10.1038/s41586-019-1674-5
22. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a Novel Mouse Ig Superfamily Ligand That Negatively Regulates T Cell Responses. J Exp Med (2011) 208(3):577–92. doi: 10.1084/jem.20100619
23. Wiliamson MA, Zhao Y, Nowak E, Li J, Schaafsaan E, Le Mercier I, et al. VISTA Is a Checkpoint Regulator for Naive T Cell Quiescence and Peripheral Tolerance. Science (2020) 367(6475):eaay0534. doi: 10.1126/science.aay0524
24. Wang Q, He J, Flies DB, Luo L, Chen L. Programmed Death One Homolog Maintains the Pool Size of Regulatory T Cells by Promoting Their Differentiation and Stability. Sci Rep (2017) 7(1):6086. doi: 10.1038/s41598-017-06410-w
25. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-Checkpoint Proteins VISTA and PD-1 Nonredundantly Regulate Murine T Cell Responses. Proc Natl Acad Sci USA (2015) 112(21):6682–7. doi: 10.1073/pnas.1403701112
26. Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, et al. VISTA Is an Immune Checkpoint Molecule for Human T Cells. Cancer Res (2014) 74(7):1924–32. doi: 10.1158/0008-5472.CAN-13-1504
27. Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM. A Prospective Analysis of Lymphocyte Phenotype and Function Over the Course of Acute Sepsis. Crit Care (2012) 16(3):R112. doi: 10.1186/cc11404
28. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-Induced Human Lymphocyte Apoptosis and Cytokine Production in “Humanized” Mice. J Leukoc Biol (2009) 86(2):219–27. doi: 10.1189/jlb.1108115
29. Sharma A, Yang WL, Matsuo S, Wang P. Differential Alterations of Tissue T Cells Subsets After Sepsis. Immunol Lett (2015) 168(1):41–50. doi: 10.1016/j.imlet.2015.09.005
30. Tang L, Bai J, Chung CS, Lomas-Neira J, Chen Y, Huang X, et al. Active Players in Resolution of Shock/Sepsis Induced Indirect Lung Injury: Immunomodulatory Effects of Tregs and PD-1. J Leukoc Biol (2014) 96(5):809–20. doi: 10.1189/jlb.0411A1213-647RR
31. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL, et al. Adoptive Transfer of In Vitro-Stimulated CD4+CD25+ Regulatory T Cells Increases Bacterial Clearance and Improves Survival in Polymicrobial Sepsis. J Immunol (2005) 174(11):7141–6. doi: 10.4049/jimmunol.174.11.1741
32. Kuhlhorn F, Rath M, Schmoeckel K, Cziupka K, Nguyen HH, Hildebrandt P, et al. FOXP3+ Regulatory T Cells Are Required for Recovery From Severe Sepsis. PLoS One (2013) 8(5):e56109. doi: 10.1371/journal.pone.0056109
33. Andrade MMC, Ariga SSK, Barbeiro DF, Barbeiro HV, Pimentel RN, Petroni RC, et al. Endotoxin Tolerance Modulates TREG and TH17 Lymphocytes Protecting Septic Mice. Oncotarget (2019) 10(37):3451–61. doi: 10.18632/oncotarget.26919
34. Hubbard WF, Choudhry M, Schwachga MG, Kerby JD, Rue LW3rd, Bland KL, et al. Cecal Ligation and Puncture. Shock (2005) 24(Suppl 1):52–7. doi: 10.1097/01.shk.0000191414.94616.7e
35. Rettrich D, Huber-Lang MS, Flies DB, Ward PA. Immunodesign of Experimental Sepsis by Cecal Ligation and Puncture. Nat Protoc (2009) 4(1):31–6. doi: 10.1038/nprot.2008.214
